These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 14688699)

  • 21. Safety and efficacy of edoxaban, an oral factor Xa inhibitor, versus enoxaparin for thromboprophylaxis after total knee arthroplasty: the STARS E-3 trial.
    Fuji T; Wang CJ; Fujita S; Kawai Y; Nakamura M; Kimura T; Ibusuki K; Ushida H; Abe K; Tachibana S
    Thromb Res; 2014 Dec; 134(6):1198-204. PubMed ID: 25294589
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Does clopidogrel increase blood loss following coronary artery bypass surgery?
    Chu MW; Wilson SR; Novick RJ; Stitt LW; Quantz MA
    Ann Thorac Surg; 2004 Nov; 78(5):1536-41. PubMed ID: 15511426
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of Enoxaparin Dosing as a Risk Factor for Bleeding in Lung Transplant Recipients.
    Sofjan AK; Iuppa JA; Bain KB; Deal EN; Witt CA; Hachem RR; Yusen RD
    Ann Pharmacother; 2016 Oct; 50(10):824-31. PubMed ID: 27363845
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Aprotinin decreases postoperative bleeding and number of transfusions in patients on clopidogrel undergoing coronary artery bypass graft surgery: a double-blind, placebo-controlled, randomized clinical trial.
    van der Linden J; Lindvall G; Sartipy U
    Circulation; 2005 Aug; 112(9 Suppl):I276-80. PubMed ID: 16159831
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A comparison of low vs conventional-dose heparin for minimal cardiopulmonary bypass in coronary artery bypass grafting surgery.
    Fromes Y; Daghildjian K; Caumartin L; Fischer M; Rouquette I; Deleuze P; Bical OM
    Anaesthesia; 2011 Jun; 66(6):488-92. PubMed ID: 21501130
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association Between Enoxaparin Dosage Adjusted by Anti-Factor Xa Trough Level and Clinically Evident Venous Thromboembolism After Trauma.
    Ko A; Harada MY; Barmparas G; Chung K; Mason R; Yim DA; Dhillon N; Margulies DR; Gewertz BL; Ley EJ
    JAMA Surg; 2016 Nov; 151(11):1006-1013. PubMed ID: 27383732
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anti-Xa activity relates to survival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin.
    Montalescot G; Collet JP; Tanguy ML; Ankri A; Payot L; Dumaine R; Choussat R; Beygui F; Gallois V; Thomas D
    Circulation; 2004 Jul; 110(4):392-8. PubMed ID: 15249498
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Early ambulation and variability in anticoagulation during elective coronary stenting with a single intravenous bolus of low-dose, low-molecular weight heparin enoxaparin.
    Zalc S; Lemos PA; Esteves A; Ribeiro EE; Horta P; Nicolau JC; Ramires JA; Cohen M; Martinez EE
    J Invasive Cardiol; 2006 Feb; 18(2):45-8. PubMed ID: 16446514
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Postoperative anticoagulation in vascular surgery: part 1. A retrospective comparison of clinical outcomes for unfractionated heparin versus low-molecular-weight heparin.
    Gramse CA; Hingorani A; Ascher E
    J Vasc Nurs; 2001 Jun; 19(2):42-9; quiz 50-1. PubMed ID: 11395717
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease.
    Merli G; Spiro TE; Olsson CG; Abildgaard U; Davidson BL; Eldor A; Elias D; Grigg A; Musset D; Rodgers GM; Trowbridge AA; Yusen RD; Zawilska K;
    Ann Intern Med; 2001 Feb; 134(3):191-202. PubMed ID: 11177331
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency.
    Lim W; Dentali F; Eikelboom JW; Crowther MA
    Ann Intern Med; 2006 May; 144(9):673-84. PubMed ID: 16670137
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Platelet activity measured by a rapid turnaround assay identifies coronary artery bypass grafting patients at increased risk for bleeding and transfusion complications after clopidogrel administration.
    Rosengart TK; Romeiser JL; White LJ; Fratello A; Fallon E; Senzel L; Shroyer AL
    J Thorac Cardiovasc Surg; 2013 Nov; 146(5):1259-1266, 1266.e1; discussion 1266. PubMed ID: 23953984
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Heparin-bonded circuits with a reduced anticoagulation protocol in primary CABG: a prospective, randomized study.
    Aldea GS; Doursounian M; O'Gara P; Treanor P; Shapira OM; Lazar HL; Shemin RJ
    Ann Thorac Surg; 1996 Aug; 62(2):410-7; discussion 417-8. PubMed ID: 8694599
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A randomized comparative study of using enoxaparin instead of unfractionated heparin in the intervention treatment of coronary heart disease.
    Chen JL; Chen J; Qiao SB; Guo YL; Wu YJ; Dai J; Yuan JQ; Qin XW; Yang YJ; Gao RL
    Chin Med J (Engl); 2006 Mar; 119(5):355-9. PubMed ID: 16542576
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of stage 3B chronic kidney disease on thrombosis and bleeding outcomes after orthopedic surgery in patients treated with desirudin or enoxaparin: insights from a randomized trial.
    Shorr AF; Eriksson BI; Jaffer AK; Smith J
    J Thromb Haemost; 2012 Aug; 10(8):1515-20. PubMed ID: 22672318
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention 1-year results from the STEEPLE (SafeTy and efficacy of enoxaparin in percutaneous coronary intervention patients, an international randomized evaluation) trial.
    Montalescot G; Gallo R; White HD; Cohen M; Steg PG; Aylward PE; Bode C; Chiariello M; King SB; Harrington RA; Desmet WJ; Macaya C; Steinhubl SR;
    JACC Cardiovasc Interv; 2009 Nov; 2(11):1083-91. PubMed ID: 19926048
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A direct comparison of intravenous enoxaparin with unfractionated heparin in primary percutaneous coronary intervention (from the ATOLL trial).
    Collet JP; Huber K; Cohen M; Zeymer U; Goldstein P; Pollack C; Silvain J; Henry P; Varenne O; Carrié D; Coste P; Angioi M; Le Breton H; Cayla G; Elhadad S; Teiger E; Filippi E; Aout M; Vicaut E; Montalescot G;
    Am J Cardiol; 2013 Nov; 112(9):1367-72. PubMed ID: 24012033
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reexploration for bleeding after coronary artery bypass surgery: risk factors, outcomes, and the effect of time delay.
    Karthik S; Grayson AD; McCarron EE; Pullan DM; Desmond MJ
    Ann Thorac Surg; 2004 Aug; 78(2):527-34; discussion 534. PubMed ID: 15276512
    [TBL] [Abstract][Full Text] [Related]  

  • 39. No difference in bleeding risk between subcutaneous enoxaparin and heparin for thromboprophylaxis in end-stage renal disease.
    Chan KE; Thadhani RI; Maddux FW
    Kidney Int; 2013 Sep; 84(3):555-61. PubMed ID: 23677243
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effect of protamine dosing variation on bleeding and transfusion after heparinisation for cardiopulmonary bypass.
    Kunz SA; Miles LF; Ianno DJ; Mirowska-Allen KL; Matalanis G; Bellomo R; Seevanayagam S
    Perfusion; 2018 Sep; 33(6):445-452. PubMed ID: 29544405
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.